XERS
Xeris Biopharma Holdings, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +1.9% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 50.72K | $516,766 | n/a | n/a |
| Q2 2026 | 94 | +4 | 81.60M | $645.79M | +9 | −4 |
| Q1 2026 | 92 | +4 | 77.44M | $449.36M | +7 | −4 |
| Q4 2025 | 88 | +2 | 77.86M | $611.14M | +3 | n/a |
| Q3 2025 | 17 | 0 | 48.63M | $395.88M | +1 | −2 |
| Q2 2025 | 15 | -1 | 41.39M | $193.31M | n/a | −1 |
| Q1 2025 | 13 | +3 | 18.95M | $104.02M | +4 | −1 |
| Q4 2024 | 10 | +1 | 14.55M | $49.32M | +1 | n/a |
| Q3 2024 | 8 | -1 | 9.23M | $26.32M | n/a | −1 |
| Q2 2024 | 9 | n/a | 8.75M | $19.69M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 11.54M | n/a | $53.87M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (passive) | 9.82M | n/a | $45.85M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | D. E. Shaw & Co. ✦ | 3.84M | +25.6% | $17.91M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (passive) | 3.78M | +13.8% | $17.67M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 3.65M | +7.2% | $17.05M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Millennium Management ✦ | 2.93M | +26.6% | $13.70M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 2.06M | -5.0% | $9.60M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 1.21M | +36.4% | $5.67M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 1.05M | +10.8% | $4.90M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 10 | Norges Bank ✦ (passive) | 561.70K | -31.8% | $2.62M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Wellington Management ✦ | 399.29K | +1.8% | $1.86M | 0.0% | ▲ Add | 5 | SEC ↗ ×3 |
| 12 | Fidelity (FMR) ✦ | 326.42K | n/a | $1.52M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 13 | T. Rowe Price ✦ | 153.27K | -13.1% | $716,000 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Point72 Asset Management ✦ | 45.10K | -49.0% | $210,617 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 32.77K | +101.9% | $153,017 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $7.40M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 229 holders, 93.59M shares, $532.36M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 25.00K sh · $250,000
Officer · 16.67K sh · $141,434
Officer · 15.00K sh · $127,308
Officer · 5.00K sh · $42,500
Officer · 5.00K sh · $42,500
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology